---
title: "SLC: Plans to establish a joint venture with a biopharmaceutical company, with a registered capital of 50 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254948888.md"
description: "SLC announced a joint venture with Shanghai Waigaoqiao Biomedical Industry Development Co., Ltd. to establish Shanghai Changlian Baifu Pharmaceutical Co., Ltd., with a registered capital of 50 million yuan. SLC will contribute 30 million yuan for a 60% stake, while the biomedical company will contribute 20 million yuan for a 40% stake. This investment will not have a significant impact on the company's revenue, profit, or cash flow in the short term. The transaction is a related party transaction but does not constitute a major asset reorganization, and has been approved by the board of directors and the supervisory board, without the need for shareholder meeting approval"
datetime: "2025-08-28T08:15:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254948888.md)
  - [en](https://longbridge.com/en/news/254948888.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254948888.md)
---

# SLC: Plans to establish a joint venture with a biopharmaceutical company, with a registered capital of 50 million yuan

SLC announced that the company plans to jointly establish Shanghai Changlian Baifu Pharmaceutical Co., Ltd. with Shanghai Waigaoqiao Biomedical Industry Development Co., Ltd. The registered capital of the new company is 50 million yuan, of which SLC will contribute 30 million yuan, accounting for 60% of the shares; the biomedical company will contribute 20 million yuan, accounting for 40% of the shares. This investment will not have a significant impact on the company's revenue, profit, or cash flow in the short term. The transaction constitutes a related party transaction but does not constitute a major asset reorganization. This transaction has been approved in advance by the special meeting of the company's independent directors and the audit committee meeting, and has been reviewed and approved by the 12th meeting of the 4th board of directors and the 10th meeting of the 4th supervisory board, and does not need to be submitted to the company's shareholders' meeting for approval

### Related Stocks

- [603648.CN](https://longbridge.com/en/quote/603648.CN.md)

## Related News & Research

- [11:16 ETHaier ist die einzige IoT-Ökosystemmarke der Welt, die acht Jahre in Folge in die Kantar BrandZ Top 100 aufgenommen wurde](https://longbridge.com/en/news/286792596.md)
- [Barnes & Noble CEO is fine with stocking AI-written books — if they're labeled. The internet had thoughts.](https://longbridge.com/en/news/287084103.md)
- [Dahlonega Now a ‘Gig-Ready’ Community from Kinetic’s Fiber-Optic Network Expansion](https://longbridge.com/en/news/287079090.md)
- [Trump to attend G7 summit in France, Axios reports](https://longbridge.com/en/news/286977541.md)
- [Allen & Heath Rolls Out New SQ+ Lineup of Digital Mixers Announced; First Look YouTube Video on SQ5+,   SQ6+, and   SQ7+ Digital Mixers at B&H](https://longbridge.com/en/news/287101198.md)